The Significance of Circulating Basophils as Predictors of Tumor Aggressiveness in Clear-Cell Renal Cell Carcinoma.

IF 1.4 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2025-05-26 DOI:10.1111/ajco.14196

Burak Arslan, Hakan Ceylan, Oguzhan Cura, Mert Kahraman, Sibel Bektas, Sina Kardas, Mustafa Gökhan Köse, Mücahit Gelmis, Ali Ayten, Ali Güler

{"title":"The Significance of Circulating Basophils as Predictors of Tumor Aggressiveness in Clear-Cell Renal Cell Carcinoma.","authors":"Burak Arslan, Hakan Ceylan, Oguzhan Cura, Mert Kahraman, Sibel Bektas, Sina Kardas, Mustafa Gökhan Köse, Mücahit Gelmis, Ali Ayten, Ali Güler","doi":"10.1111/ajco.14196","DOIUrl":null,"url":null,"abstract":"Aim: Our aim was to investigate the value of basophils in predicting tumor aggressiveness in clear-cell renal cell carcinoma (ccRCC).Methods: Baseline characteristics of 183 patients were recorded. Receiver operating characteristic (ROC) curve analysis was performed to calculate the cut-off value for basophil count in predicting the presence of perirenal and/or renal sinus fat involvement, as well as a high-grade WHO/ISUP score. Regression analyses were performed to determine the independent risk factors for perirenal/renal sinus fat invasion and a high-grade WHO/ISUP score.Results: The ROC curve analysis showed that the cut-off value of basophil count was 0.045 for the presence of a high-grade WHO/ISUP score (AUC = 0.769) and perirenal and/or renal sinus fat involvement (AUC = 0.731). Tumor size (p = 0.013), high WHO/ISUP grade (p = 0.036), LVI (p = 0.028), perirenal/renal sinus fat involvement (p = 0.043), and advanced (3-4) TNM stage (0.012) were significantly higher in patients with basophil count ≥ 0.045. In multivariate analysis, tumor size (OR = 1.10), LVI (OR = 3.35), and preoperative basophil count ≥ 0.045 (OR = 3.65) were found to be independent predictors for the presence of a high-grade WHO/ISUP score. Similarly, tumor size (OR = 1.21), high WHO/ISUP grade (OR = 2.44), and preoperative basophil count ≥ 0.045 (OR = 1.96) were found to be independent predictors for the presence of perirenal and/or renal sinus fat involvement in multivariate analysis.Conclusion: Our results demonstrated that preoperative basophil count emerges as a valuable predictor of tumor aggressiveness in ccRCC, offering a readily accessible biomarker to aid in the management of this malignancy.","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.14196","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Our aim was to investigate the value of basophils in predicting tumor aggressiveness in clear-cell renal cell carcinoma (ccRCC).

Methods: Baseline characteristics of 183 patients were recorded. Receiver operating characteristic (ROC) curve analysis was performed to calculate the cut-off value for basophil count in predicting the presence of perirenal and/or renal sinus fat involvement, as well as a high-grade WHO/ISUP score. Regression analyses were performed to determine the independent risk factors for perirenal/renal sinus fat invasion and a high-grade WHO/ISUP score.

Results: The ROC curve analysis showed that the cut-off value of basophil count was 0.045 for the presence of a high-grade WHO/ISUP score (AUC = 0.769) and perirenal and/or renal sinus fat involvement (AUC = 0.731). Tumor size (p = 0.013), high WHO/ISUP grade (p = 0.036), LVI (p = 0.028), perirenal/renal sinus fat involvement (p = 0.043), and advanced (3-4) TNM stage (0.012) were significantly higher in patients with basophil count ≥ 0.045. In multivariate analysis, tumor size (OR = 1.10), LVI (OR = 3.35), and preoperative basophil count ≥ 0.045 (OR = 3.65) were found to be independent predictors for the presence of a high-grade WHO/ISUP score. Similarly, tumor size (OR = 1.21), high WHO/ISUP grade (OR = 2.44), and preoperative basophil count ≥ 0.045 (OR = 1.96) were found to be independent predictors for the presence of perirenal and/or renal sinus fat involvement in multivariate analysis.

Conclusion: Our results demonstrated that preoperative basophil count emerges as a valuable predictor of tumor aggressiveness in ccRCC, offering a readily accessible biomarker to aid in the management of this malignancy.

查看原文本刊更多论文

循环嗜碱性粒细胞作为透明细胞肾细胞癌肿瘤侵袭性预测因子的意义。

目的：探讨嗜碱性粒细胞在透明细胞肾细胞癌（ccRCC）中预测肿瘤侵袭性的价值。方法：记录183例患者的基线特征。进行受试者工作特征（ROC）曲线分析，计算嗜碱性粒细胞计数预测肾周和/或肾窦脂肪累及的临界值，以及WHO/ISUP评分。进行回归分析以确定肾周/肾窦脂肪侵入的独立危险因素和高级别WHO/ISUP评分。结果：ROC曲线分析显示，嗜碱性粒细胞计数的临界值为0.045，存在高级别WHO/ISUP评分（AUC = 0.769）和肾周和/或肾窦脂肪累及（AUC = 0.731）。在嗜碱性粒细胞计数≥0.045的患者中，肿瘤大小（p = 0.013）、WHO/ISUP高分级（p = 0.036）、LVI （p = 0.028）、肾周/肾窦脂肪累及（p = 0.043）和TNM晚期（3-4）分期（0.012）显著增加。在多变量分析中，肿瘤大小（OR = 1.10）、LVI （OR = 3.35）和术前嗜碱性粒细胞计数≥0.045 （OR = 3.65）被发现是WHO/ISUP评分高级别存在的独立预测因子。同样，在多变量分析中，肿瘤大小（OR = 1.21）、高WHO/ISUP分级（OR = 2.44）和术前嗜碱性粒细胞计数≥0.045 （OR = 1.96）被发现是肾周和/或肾窦脂肪累及的独立预测因素。结论：我们的研究结果表明，术前嗜碱性粒细胞计数是ccRCC肿瘤侵袭性的一个有价值的预测指标，为这种恶性肿瘤的治疗提供了一个容易获得的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.